about
Anatomical effects of dexamethasone intravitreal implant in diabetic macular oedema: a pooled analysis of 3-year phase III trialsDevelopment of onabotulinumtoxinA for chronic migraineLocal methotrexate and dexamethasone phosphate for the treatment of recurrent primary intraocular lymphoma.Early and Long-Term Responses to Anti-Vascular Endothelial Growth Factor Therapy in Diabetic Macular Edema: Analysis of Protocol I Data.Bimatoprost 0.03% for the Treatment of Eyebrow HypotrichosisDexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results.A randomized, controlled comparison of macroscopic conjunctival hyperemia in patients treated with bimatoprost 0.01% or vehicle who were previously controlled on latanoprostTwice-daily 0.2% brimonidine-0.5% timolol fixed-combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension: a 12-month randomized trial.Recent advances in ocular therapeutics.Ophthalmic drug delivery systems for the treatment of retinal diseases: basic research to clinical applications.Dexamethasone intravitreal implant in combination with laser photocoagulation for the treatment of diffuse diabetic macular edema.Long-term safety evaluation of bimatoprost ophthalmic solution 0.03%: a pooled analysis of six double-masked, randomized, active-controlled clinical trials.Dexamethasone intravitreal implant in previously treated patients with diabetic macular edema: subgroup analysis of the MEAD study.INTRAOCULAR PRESSURE IN PATIENTS WITH DIABETIC MACULAR EDEMA TREATED WITH DEXAMETHASONE INTRAVITREAL IMPLANT IN THE 3-YEAR MEAD STUDY.The role of the immune response in age-related macular degenerationInflammation in retinal diseaseClinical trials in neuroprotection.Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema.Normative comparison of patient-reported outcomes in patients with noninfectious uveitis.Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis.Development of a dexamethasone intravitreal implant for the treatment of noninfectious posterior segment uveitis.Bimatoprost Sustained-Release Implants for Glaucoma Therapy: 6-Month Results From a Phase I/II Clinical Trial.Eyelash growth in subjects treated with bimatoprost: a multicenter, randomized, double-masked, vehicle-controlled, parallel-group study.Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema.A randomized, investigator-masked comparison of diurnal responder rates with bimatoprost and latanoprost in the lowering of intraocular pressure.Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion.LAP-BAND for lower BMI: 2-year results from the multicenter pivotal study.One-year, randomized study comparing bimatoprost and timolol in glaucoma and ocular hypertension.A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma.A 3-month comparison of efficacy and safety of brimonidine-purite 0.15% and brimonidine 0.2% in patients with glaucoma or ocular hypertension.A 3-month randomized controlled trial of bimatoprost (LUMIGAN) versus combined timolol and dorzolamide (Cosopt) in patients with glaucoma or ocular hypertension.Efficacy and tolerability of ophthalmic epinastine assessed using the conjunctival antigen challenge model in patients with a history of allergic conjunctivitis.Efficacy and tolerability of ophthalmic epinastine: a randomized, double-masked, parallel-group, active- and vehicle-controlled environmental trial in patients with seasonal allergic conjunctivitis.Two-year double-masked comparison of bimatoprost with timolol in patients with glaucoma or ocular hypertension.Treatment of rabbit corneal infections with ophthalmic gatifloxacin: a concentration dependence study.Treatment of experimental anterior and intermediate uveitis by a dexamethasone intravitreal implant.Effects of the preservative purite on the bioavailability of brimonidine in the aqueous humor of rabbits.Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema.Immunotolerance toward native alphaA-crystallin in knockout mice deficient in the functional protein.Vascular changes in eyes treated with dexamethasone intravitreal implant for macular edema after retinal vein occlusion.
P50
Q24658545-C92EB377-7B95-4C13-B71E-28A82FF465D4Q27027006-4EA96587-3342-4078-94F4-834ABC01D282Q30712188-93FD9A3A-752F-4D3B-B80A-8C2BFD92293DQ31131704-CDB8A0E2-654A-43AD-838B-ABD392F6FED0Q33631865-B002F822-2BEE-4A1F-B569-2432916375C7Q34201060-76C47941-C50F-44DD-9031-B936C5D5BF24Q34399842-EB119668-2033-4B2C-A4B8-8A4F5001933BQ34565322-2A5AE646-37A2-4011-976D-BF92471A3096Q34576200-67BF9DE6-9DF3-47FB-B4B9-E1F6FA586555Q34701929-ED4ABE9F-40B8-496B-B9FC-144C640F4679Q34740231-EAFFB44F-6509-498F-975B-386670D734B7Q35050234-CA704E7B-4486-4E07-9B9B-EAB9613F8C8BQ35828114-7280B3D3-A2B9-47FD-A9AF-CE3E006D29A3Q35922054-B03A64FF-1C4C-49BC-A06A-4C32671D0ED2Q36914129-85680F4F-AEEF-41FD-8A48-C67B98E89B12Q37200268-4D9AB0BF-73FF-435C-A31F-F0D39D9F5D28Q37301629-107863B8-6A11-41DF-9969-C1B59506DF68Q38375238-E68BA1D7-3D05-451B-A757-122468460B76Q38456029-8834A388-B3A9-4EFA-AB84-AD1AB94D6CF2Q38495949-AA6252DB-64EF-47EC-A5F7-7D4F7549AAD8Q38552030-80454BCF-191F-48C6-ACEA-80615B5C1D2FQ39066647-01DD912B-6121-4AA2-BDD7-7EF555569242Q39997886-7CB697D9-7179-4B40-A877-4E02E51A749CQ42165531-200F2AB1-CE03-4F16-948F-87AA8FAACE77Q42622037-FD870D66-9F07-427C-8555-6D3206C53F3DQ43086468-D24E3054-3A15-4295-A457-B0B8574F2517Q43525499-B657C249-DB36-4B4D-8B7E-435648ABA91AQ44169166-827F5C55-83C0-4AB7-A303-67F4E9BF2C6AQ44264227-CE616639-EB40-45A9-A564-C38436180E6AQ44369548-0EEC4495-B93D-4FE9-897F-20790F3F3809Q44673679-AEB513F5-5608-4B71-A2E6-EB63EA9E21E6Q44729620-F64AB609-FA74-4C46-996D-5BEF0A784A5EQ44783739-B5B32862-19BD-464B-9558-562E3800D41FQ44796842-15F3CA57-1427-4893-B83C-A906F8B79F16Q44931858-84AE4D34-B039-46A9-B655-FDCE7342FC1EQ44987368-2E32AE18-80AB-4215-B404-FA0F98ADBE59Q45024428-A6927562-94B2-4A76-95F7-E6E530BB0FD3Q45133527-621CB14A-3120-4804-B47C-FDB0FDA3E246Q45869476-7353405C-73D7-4C15-8276-B41B40B0192CQ45940802-B0943B5E-4654-4BC4-912B-582BFD2C582B
P50
name
Scott M Whitcup
@en
Scott M Whitcup
@nl
type
label
Scott M Whitcup
@en
Scott M Whitcup
@nl
prefLabel
Scott M Whitcup
@en
Scott M Whitcup
@nl